Compare Bristol-Myers Squibb Co (BMY) vs Check Point Software Technologies Ltd (CHKP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Check Point Software Technologies Ltd — how do they compare? Bristol-Myers Squibb Co trades at $63.94 (market cap $129.94B), while Check Point Software Technologies Ltd trades at $128.21 (market cap $13.18B). The key difference: Bristol-Myers Squibb Co is far larger — about 9.9× Check Point Software Technologies Ltd's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Check Point Software Technologies Ltd pays none. Which is the better fit depends on your goals.
| BMY | CHKP | |
|---|---|---|
Market Cap | $129.94B | $13.18B |
Sector | Health | Technology |
52-Week High | $65.89 | $206.91 |
52-Week Low | $42.60 | $112.47 |
Enterprise Value | $163.92B | $12.88B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Check Point Software Technologies (CHKP) trades at $128.21, down 2.23% on the day, reflecting recent bearish pressure. The stock shows strong profitability with a net margin of 37.93% and has beaten earnings estimates for three consecutive quarters. Technical indicators signal a bearish trend, with the price near support at $128. Recent news highlights AI security growth potential and insider selling activity.
The outlook is mixed: valuation appears attractive with a P/E of 13.24, but growth challenges and margin pressures pose risks. Analyst consensus leans neutral with a $146.92 price target, suggesting cautious optimism for recovery driven by AI security demand, though competitive and execution risks remain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →
